Johnson & Johnson $JNJ Stock: Goelzer Investment Management Inc. Decreases Holdings

Goelzer Investment Management Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJ) by 40.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 53,901 shares of the company’s stock after selling 36,564 shares during the quarter. Johnson & Johnson accounts for approximately 0.6% of Goelzer Investment Management Inc.’s investment portfolio, making the stock its 27th biggest holding. Goelzer Investment Management Inc.’s holdings in Johnson & Johnson were worth $14,270,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co boosted its stake in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares during the last quarter. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $43,000. Polaris Financial Partners acquired a new stake in Johnson & Johnson during the third quarter worth about $56,000. Finally, Bullseye Investment Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at approximately $63,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $255.54 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a fifty day moving average of $265.66 and a 200 day moving average of $249.61. The firm has a market cap of $615.82 billion, a PE ratio of 38.72, a PEG ratio of 2.53 and a beta of 0.21. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. The company’s revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson?
• Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target.
• Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying
• Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss
• Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Johnson Rice reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, August 3rd. Bank of America restated a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Citigroup raised their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, Morgan Stanley cut their target price on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $274.87.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.